Faye L Abbesse

Researchers are evaluating the effects of transcranial direct current stimulation (tDCS) on reducing suicidal thoughts in adults diagnosed with treatment-resistant depression. The study focuses on patients experiencing recurrent or isolated depressive episodes who have suicidal ideation, aiming to assess whether 15 sessions of tDCS can help manage these symptoms. This pilot study includes patients who are on stable antidepressant treatment and meet specific depression and suicide ideation scores. Participants receive one 30-minute tDCS session daily for 15 days, each at an intensity of 2 mA. After completing the 15 sessions, patients return for three follow-up visits on days 19, 49, and 79 to monitor changes and effects. The treatment involves a device delivering the stimulation directly to the brain area targeted to reduce suicidal ideation. During the study, patients undergo initial screening to confirm eligibility, including diagnosis and treatment stability. Researchers measure changes in suicidal thoughts using the Scale for Suicide Ideation at baseline and day 19. Follow-up visits continue monitoring symptoms and safety. Participants' adherence and health are tracked throughout the treatment and follow-up periods, with the total study duration extending to approximately 79 days post-treatment start.

Researchers are conducting the Dataids cohort, a long-term prospective study involving over 30,000 HIV-infected patients receiving care at more than 15 HIV centers across France. The study aims to monitor clinical practices, track changes in the course of HIV and related infections, and evaluate factors influencing the clinical, immunological, and virological progression of HIV. It also focuses on assessing antiretroviral therapy (ART) effectiveness and monitoring hepatitis C virus (HCV) treatment outcomes. Participants in the study include HIV-1 infected patients regardless of their CD4 cell count or ART status. Data collection occurs as part of routine outpatient clinic visits, with annual gathering of demographic, immunological, virological, serological, laboratory, therapeutic, and clinical information. The cohort has been ongoing since 2010, reflecting real-world clinical care and treatment patterns in France. Throughout the study, researchers track participants’ HIV plasma viral load to evaluate treatment success, specifically measuring the proportion of patients with viral loads below 50 copies/mL over an average of six months from enrollment. Data on co-infections such as hepatitis B and C, as well as syphilis, are also collected. This observational design allows ongoing surveillance of HIV infection trends and treatment effectiveness, supporting improved care quality for HIV patients in France.